Société Pluristem Therapeutics Inc. Nasdaq
Actions
US72940R1023
Recherche biotechnologique et médicale
Métier
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/11/06 |
Director of Finance/CFO | 40 | 01/05/13 | |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/22 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/21 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/11 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01/10/14 |
Human Resources Officer | 62 | 01/01/07 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 73 | 15/07/21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11/07/23 |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/11/06 |
Director/Board Member | 54 | 06/01/21 | |
Director/Board Member | 61 | 01/06/21 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 5 388 792 | 4 101 934 ( 76,12 %) | 0 | 76,12 % |
Coordonnées société
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+17,96% | 44,96 Md | |
+1,17% | 42,65 Md | |
+48,77% | 41,85 Md | |
-4,27% | 29,04 Md | |
+11,42% | 26,08 Md | |
-21,39% | 19,03 Md | |
+4,86% | 12,75 Md | |
+27,29% | 12,06 Md | |
-3,50% | 11,75 Md |